Abstract The US Food and Drug Administration has approved a total of 37 new drugs in
2022, which are composed of 20 chemical entities and 17 biologics. In particular, 20 …

Over the last two decades, several epi‐drugs, immune checkpoint inhibitors (ICIs) and
adoptive cell therapies have received clinical approval for use in certain types of cancer …

Chemoresistant leukemia relapse is one of the most common causes of death for acute
myeloid leukemia (AML) patients and the homing/engraftment in bone marrow (BM) are …

Relapse is a leading cause of death after allogeneic hematopoietic stem cell transplantation
(allo-HSCT) for acute myeloid leukemia (AML). However, the underlying mechanisms …

DNA methyltransferase inhibitors (DNMTis) reexpress hypermethylated genes in cancers
and leukemias and also activate endogenous retroviruses (ERVs), leading to interferon …

Acute myeloid leukemia (AML) is a heterogeneous disease developed from the malignant
expansion of myeloid precursor cells in the bone marrow and peripheral blood. The …

Human caseinolytic protease P (ClpP) is required for the regulatory hydrolysis of
mitochondrial proteins. Allosteric ClpP agonists dysfunctionally activate mitochondrial ClpP …

Exosomal long non-coding RNAs (lncRNAs) have emerged as a cell-free biomarker for
clinical evaluation of cancers. However, the potential clinical applications of exosomal …

Leukemia is a malignancy initiated by uncontrolled proliferation of hematopoietic stem cell
from the B and T lineages, resulting in destruction of hematopoietic system. The …

Background Cuproptosis is a type of programmed cell death that is involved in multiple
physiological and pathological processes, including cancer. We constructed a prognostic …